Send to

Choose Destination
Virology. 1994 Apr;200(1):236-45.

Vaccination with the immediate-early protein ICP47 of herpes simplex virus-type 1 (HSV-1) induces virus-specific lymphoproliferation, but fails to protect against lethal challenge.

Author information

Department of Microbiology, University of Tennessee, Knoxville 37996-0845.


Assessing the immunobiological function of the individual proteins of herpes simplex virus-type 1 (HSV-1) continues to be important in elucidating virus-host interactions and for the rational design of subunit vaccines. In this report, the non-structural, immediate-early protein ICP47 of HSV-1 was examined for its ability to induce virus-specific immune responses. The ICP47 protein, when expressed from a recombinant vaccinia virus or when produced by cell-free, in vitro translation, induced a vigorous HSV-1-specific lymphoproliferative response. However, other common parameters of immunity such as neutralizing antibody, delayed-type hypersensitivity, and class I major histocompatibility complex (MHC)-restricted cytotoxic T lymphocytes (CTL) were not induced by ICP47. Moreover, mice immunized with vaccinia-expressed ICP47 were unable to survive lethal challenge with virulent HSV, indicating that in spite of its ability to induce significant HSV-1-specific lymphoproliferation, ICP47 appears unable to afford protective immunity in vivo. Possible reasons for this failure and the implications of these results in terms of vaccine design are discussed.

[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Elsevier Science
Loading ...
Support Center